Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Cash & Current Investments (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Cash & Current Investments data on record, last reported at $5.3 million in Q3 2025.

  • For Q3 2025, Cash & Current Investments rose 368.61% year-over-year to $5.3 million; the TTM value through Sep 2025 reached $5.3 million, up 368.61%, while the annual FY2024 figure was $532885.0, 63.73% down from the prior year.
  • Cash & Current Investments reached $5.3 million in Q3 2025 per COEP's latest filing, up from $3.0 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $7.4 million in Q3 2022 and bottomed at $532885.0 in Q4 2024.
  • Average Cash & Current Investments over 5 years is $2.4 million, with a median of $2.1 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: soared 1160.77% in 2022, then tumbled 80.85% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $2.2 million in 2021, then skyrocketed by 73.95% to $3.8 million in 2022, then tumbled by 61.25% to $1.5 million in 2023, then tumbled by 63.73% to $532885.0 in 2024, then surged by 900.25% to $5.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $5.3 million in Q3 2025, $3.0 million in Q2 2025, and $4.3 million in Q1 2025.